The **FDA** has approved intravenous **atezolizumab** in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III mismatch repair-deficient (dMMR) colon cancer in patients 2 years and older. Additionally, the agency approved the subcutaneous form of **atezolizumab** (with hyaluronidase) for patients 12 years and older weighing at least 88 lb.
A randomized trial, ATOMIC/ML39057, involving 711 patients with stage III dMMR colon cancer, demonstrated a 50% reduction in the risk of disease recurrence or death with the addition of **atezolizumab** to standard adjuvant chemotherapy. The 3-year disease-free survival rate was 86% with atezolizumab plus chemotherapy compared to 76% with chemotherapy alone (HR 0.50, 95% CI 0.35-0.73, P<0.0001). A subgroup analysis of patients with dMMR cancer confirmed this HR of 0.53 (95% CI 0.36-0.79, P=0.0007). Grade ≥3 adverse events were more frequent in the atezolizumab arm (71.7% vs 62.1%). The safety profile of atezolizumab plus chemotherapy was consistent with the known effects of the drugs.